8-K: Benitec Biopharma Prices $30 Million Common Stock Offering

Benitec Biopharma Inc. announces the pricing of a $30 million offering of common stock and pre-funded warrants, including a concurrent registered direct offering with Suvretta Capital.

Summary

• Benitec Biopharma Inc. has announced the pricing of its underwritten offering of 1,443,000 shares of common stock (or pre-funded warrants) and a concurrent registered direct offering of 900,000 shares of common stock with Suvretta Capital.
• The offering price is $13.00 per share of common stock and $12.9999 per pre-funded warrant.
• The pre-funded warrants are immediately exercisable at $0.0001 per share.
• The offerings are expected to close on March 26, 2025, subject to customary closing conditions.
• The aggregate gross proceeds are expected to be approximately $30 million before deducting underwriting discounts, commissions, and other offering expenses.
• Benitec intends to use the net proceeds to support the continued development of its product candidate programs, working capital, and other general corporate purposes.
• Leerink Partners and TD Cowen are acting as bookrunning managers, and Citizens Capital Markets is acting as lead manager for the underwritten offering.
• Benitec has discussed with Suvretta Capital the appointment of David Friedman to the Company's board of directors, subject to approval.
• Kishen Mehta, a portfolio manager at Suvretta Capital, was previously appointed to the board on June 26, 2024.

Sentiment

Score: 7

Explanation: The announcement is generally positive, indicating successful capital raising efforts. However, the inherent risks associated with biotechnology companies and forward-looking statements temper the overall sentiment.

Positives

• The capital raise will provide funding to support the continued development of Benitec's product candidate programs.
• The participation of a long-term investor like Suvretta Capital may signal confidence in the company's prospects.
• The pre-funded warrants provide an option for future equity at a nominal exercise price.

Risks

• The closing of the offerings is subject to customary closing conditions and may not occur as expected.
• The use of proceeds is at the discretion of the company and may not yield the desired results.
• Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.

Future Outlook

The company intends to use the net proceeds from this financing, together with existing cash on hand, to support the continued development of its product candidate programs, working capital and other general corporate purposes.

Industry Context

This announcement reflects ongoing capital raising activity within the biotechnology sector, particularly for companies focused on developing novel genetic medicines. The involvement of specialized investment firms like Suvretta Capital is common in such financings.

Management Changes

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares.
• Employees: Continued funding for product development may provide job security.
• Investors: Opportunity to invest in a clinical-stage biotechnology company.

Next Steps

• The offerings are expected to close on March 26, 2025, subject to customary closing conditions.
• The Company intends to file a prospectus supplement relating to these offerings with the SEC.
• The Company may appoint David Friedman, managing director at Suvretta Capital, to the Companys board of directors, subject to approval.

Key Dates

Keywords

Benitec Biopharma, common stock, pre-funded warrants, offering, capital raise, Suvretta Capital, ddRNAi, genetic medicines, Leerink Partners, TD Cowen, Citizens Capital Markets